Last $5.45 USD
Change Today -0.17 / -3.02%
Volume 158.5K
NEO On Other Exchanges
As of 2:53 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $6.10
52 Week Low
09/16/13 - $2.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Mulls Acquisitions With $32 Million

Neogenomics Inc. (NasdaqCM:NEO) intends to pursue acquisitions. The company has priced an underwritten public offering of 7 million shares for gross proceeds of $32.2 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt.

Neogenomics Mulls Acquisitions

Neogenomics Inc. (NasdaqCM:NEO) is seeking acquisition opportunities. Neogenomics announced that it has commenced an underwritten public offering of shares of its common stock. NeoGenomics anticipates using the net proceeds from the offering for working capital, capital expenditures and other corporate purposes, including potential acquisitions and the repayment of debt.

Neogenomics Announces Resignation of Robert Gasparini as Chief Scientific Officer

On August 4, 2014 Neogenomics Inc. announced that Robert Gasparini, Chief Scientific Officer retired and resigned his officer position. Mr. Gasparini has agreed to continue to serve as a consultant to NeoGenomics Laboratories Inc. on a part-time basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $5.45 USD -0.17

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $29.05 USD +0.24
Foundation Medicine Inc $21.09 USD -0.35
Genomic Health Inc $28.77 USD +0.49
Response Genetics Inc $0.75 USD -0.0299
Rosetta Genomics Ltd $3.59 USD +0.0867
View Industry Companies

Industry Analysis


Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.8x
Price/Book 12.1x
Price/Cash Flow 153.0x
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at